FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W564508744> ?p ?o ?g. }

• W564508744 endingPage "17513" @default.
• W564508744 startingPage "17513" @default.
• W564508744 abstract "17513 Background: The purpose of this study was to assess medication compliance and persistency in breast, lung, and prostate cancer patients with bone metastases receiving Zoledronic acid (ZOL) in a community practice setting. Methods: This was a retrospective observational study of an electronic medical record database from a large oncology/hematology practice in southeastern United States. Patients were included with a medical diagnosis of breast, lung, or prostate cancer, followed by a medical diagnosis of bone metastases, initiation of ZOL (1/1/2004–10/1/2006) and at least 12 months of follow-up time. Compliance, or medication possession ratio (MPR), was calculated as a percentage dividing the number of days medication was available during the 12 months. Persistency was defined as time to therapy interruption evaluated over a 12-month timeframe from initiation of ZOL. Results: A total of 874, 514, and 335 patients were identified with breast, lung, and prostate cancer with bone metastatis, respectively. Approximately 85%, 70%, and 78% of breast, lung, and prostate cancer patients, respectively, were receiving a bisphosphonate. After applying inclusion criteria, 222, 59, and 93 patients with breast, lung, and prostate cancer, respectively, were included in the final analysis. Mean age was 58.7 for breast cancer, 65.1 for lung cancer, and 70.9 for prostate cancer. MPR during the 12-month timeframe was 85.4%, 82.3%, and 84.8% for breast, lung, and prostate cancer. A therapy interruption of > 35 days during the 1-year timeframe was noted in 68.5%, 74.6%, and 77.4% of breast lung, and prostate cancer patients. Of those individuals with a therapy interruption, 88.8%, 77.3%, and 81.9% restarted treatment within one year in the breast, lung, and prostate cancer cohorts, respectively. Overall, mean time to restarting treatment ranged from 53 days (SD = 20) in the prostate cancer cohort to 61 (SD = 44 and 47) days in the breast and lung cancer cohort. Conclusions: Overall, 15%, 30% and 22% of patients with breast, lung, and prostate cancer, respectively did not receive a bisphosphonate, even though they had a diagnosis of bone metastases where therapy is indicated. The majority of patients had their therapy interrupted during the course of 1 year and up to 25% did not restart treatment. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Pharmaceuticals Corporation Novartis Pharmaceuticals Corporation" @default.
• W564508744 created "2016-06-24" @default.
• W564508744 creator A5029230498 @default.
• W564508744 creator A5044542360 @default.
• W564508744 creator A5050866878 @default.
• W564508744 creator A5057657295 @default.
• W564508744 creator A5061092297 @default.
• W564508744 creator A5067395470 @default.
• W564508744 creator A5087541775 @default.
• W564508744 date "2008-05-20" @default.
• W564508744 modified "2023-09-27" @default.
• W564508744 title "Zoledronic acid compliance and persistency in bone metastases due to breast, lung, and prostate cancer" @default.
• W564508744 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.17513" @default.
• W564508744 hasPublicationYear "2008" @default.
• W564508744 type Work @default.
• W564508744 sameAs 564508744 @default.
• W564508744 citedByCount "0" @default.
• W564508744 crossrefType "journal-article" @default.
• W564508744 hasAuthorship W564508744A5029230498 @default.
• W564508744 hasAuthorship W564508744A5044542360 @default.
• W564508744 hasAuthorship W564508744A5050866878 @default.
• W564508744 hasAuthorship W564508744A5057657295 @default.
• W564508744 hasAuthorship W564508744A5061092297 @default.
• W564508744 hasAuthorship W564508744A5067395470 @default.
• W564508744 hasAuthorship W564508744A5087541775 @default.
• W564508744 hasConcept C121608353 @default.
• W564508744 hasConcept C126322002 @default.
• W564508744 hasConcept C143998085 @default.
• W564508744 hasConcept C167135981 @default.
• W564508744 hasConcept C2776235491 @default.
• W564508744 hasConcept C2776256026 @default.
• W564508744 hasConcept C2776326535 @default.
• W564508744 hasConcept C2777714996 @default.
• W564508744 hasConcept C2777783956 @default.
• W564508744 hasConcept C2780192828 @default.
• W564508744 hasConcept C530470458 @default.
• W564508744 hasConcept C71924100 @default.
• W564508744 hasConceptScore W564508744C121608353 @default.
• W564508744 hasConceptScore W564508744C126322002 @default.
• W564508744 hasConceptScore W564508744C143998085 @default.
• W564508744 hasConceptScore W564508744C167135981 @default.
• W564508744 hasConceptScore W564508744C2776235491 @default.
• W564508744 hasConceptScore W564508744C2776256026 @default.
• W564508744 hasConceptScore W564508744C2776326535 @default.
• W564508744 hasConceptScore W564508744C2777714996 @default.
• W564508744 hasConceptScore W564508744C2777783956 @default.
• W564508744 hasConceptScore W564508744C2780192828 @default.
• W564508744 hasConceptScore W564508744C530470458 @default.
• W564508744 hasConceptScore W564508744C71924100 @default.
• W564508744 hasIssue "15_suppl" @default.
• W564508744 hasLocation W5645087441 @default.
• W564508744 hasOpenAccess W564508744 @default.
• W564508744 hasPrimaryLocation W5645087441 @default.
• W564508744 hasRelatedWork W1856092259 @default.
• W564508744 hasRelatedWork W1988873325 @default.
• W564508744 hasRelatedWork W2324715925 @default.
• W564508744 hasRelatedWork W2360420010 @default.
• W564508744 hasRelatedWork W2368994420 @default.
• W564508744 hasRelatedWork W2417724487 @default.
• W564508744 hasRelatedWork W2429027331 @default.
• W564508744 hasRelatedWork W2784010975 @default.
• W564508744 hasRelatedWork W3032254165 @default.
• W564508744 hasRelatedWork W3210868775 @default.
• W564508744 hasVolume "26" @default.
• W564508744 isParatext "false" @default.
• W564508744 isRetracted "false" @default.
• W564508744 magId "564508744" @default.
• W564508744 workType "article" @default.